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Novelty Statement 
 
a) Diabetic ketoacidosis  is a commonly encountered metabolic emergency, 
but the costs of treating the condition remain unknown in the UK 
b) Using individual patient data from the 2014 national survey we conducted 
a ‘bottom-up’ approach to cost analysis 
c) The average cost of an episode of diabetic ketoacidosis in the UK in 2014 
was £2064 per patient (95% CI: £1800, 2563) 
  
  
Abstract 
 
Aims 
Diabetic ketoacidosis (DKA) is a commonly encountered metabolic 
emergency. In 2014 a national survey was conducted looking at the 
management of DKA in adult patients across the UK. The survey reported the 
clinical management of individual patients as well as institutional factors that 
teams felt were important in helping to deliver that care. However, costs of 
treating DKA were not reported.  
Methods 
We used a ‘bottom up’ approach to cost analysis to determine the total 
expense associated with treating DKA in a mixed population sample. The data 
were derived from the source data from the national UK survey of 283 
individual patients collected via questionnaires sent to hospitals across the 
country. 
Results 
Because the initial survey collection tool was not designed with a health 
economic model in mind, several assumptions were made when analysing the 
data. The mean and median time in hospital was 5.6 and 2.7 days, 
respectively. Based on the individual patient data and using the Joint British 
Diabetes Societies Inpatient Care Group guidelines, the cost analysis shows 
that for this cohort, the average cost for an episode of DKA was £2064 per 
patient (95% CI: £1800, 2563).  
Conclusion 
Despite relatively short stays in hospital, costs for managing episodes of DKA 
in adults were relatively high. Assumptions made in calculations did not take 
  
into account prolonged hospital stay due to co-morbidities nor costs incurred 
as a loss of productivity. Therefore the actual costs to the healthcare system 
and society in general are likely to be substantially higher. 
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Introduction 
Diabetic ketoacidosis (DKA) is one of the most commonly encountered 
metabolic emergencies, but incidence varies geographically. In the UK the 
crude one-year incidence has been reported as 3.6%, equating to 4.8 episodes 
per 100 patient years [1,2]. In North America the one year incidence is between 
1% and 5% of people with type 1 diabetes [3,4], equating to about 145,000 
cases per year [5]. In the Western Pacific region, the rate amongst children is 
10 per 100 patient years [6] but is much lower in some parts of Northern Europe 
[7,8]. Most cases of DKA occur in type 1 diabetes, but up to 50% of cases in 
some regions occur in those with type 2 diabetes, depending on ethnicity and 
family history [9,10]. However, those with type 1 diabetes tend to have the 
greatest metabolic derangement, with a lower pH compared to those with type 
2 diabetes [11]. Whilst there are few datasets, DKA remains an expensive 
condition to treat with individual admissions estimated to cost ~US$17,500 in 
the USA. Very little work on how much an episode of DKA costs the health 
service has been carried out until recently in the UK, and those data that have 
been produced have relied on relatively crude methods.  
 
In 2014 a national survey was carried out in the UK looking at the management 
of DKA. Briefly, this survey consisted of two parts, one looking at outcomes of 
a convenience sample of up to 5 consecutive patients presenting with DKA over 
a 7 month period. 72 out of 220 UK hospitals returned data on 283 admissions 
in 281 patients looking at all aspects of their care during the acute hospital 
admission [12]. The demographic data of these patients have been described 
previously [12]. In addition, 67 hospitals returned questionnaires on the 
institutional factors that assessed their ability to provide comprehensive care 
  
for adult patients presenting with DKA [13]. We used these datasets to conduct 
an analysis to assess how much it cost to treat DKA in adults in the UK in 2014 
 
Methods 
The cost analysis was based on an aggregation of individual-level factors 
collected as part of the questionnaire, and informed by the Joint British Diabetes 
Societies (JBDS) Inpatient Care Group guidelines [14]. The key components of 
our estimate of cost included diagnostic and laboratory assessments, nurse 
and physician contacts and drug dosages during the acute DKA phase of the 
admission, and per diem ward costs following the resolution of DKA. The 
quantity of diagnostic tests was recorded in the questionnaire, along with time 
from admission to DKA resolution and time to discharge. Healthcare staff times 
were based on expert opinion. Our key costing assumptions are detailed below, 
and unit prices are shown in Table 1.  
 Each patient was assessed for 15 minutes by a junior doctor upon 
admission. 
 Blood and urine samples were collected at admission and required 15 
minutes of nurse time. 
 All patients received intravenous insulin according to JBDS guidelines 
every hour from admission to DKA resolution. This required 15 minutes 
of nurse time and 5 minutes of junior doctor time per hour. 
 For dosing purposes, patients were assumed to weigh an average of 
70kg. 
 Assessment by members of the diabetes specialist team took 30 
minutes of nurse time. 
  
 Location of care during the DKA phase was recorded in the 
questionnaire (see Table 2) and we assumed patients were transferred 
to a general ward upon DKA resolution for the remainder of their 
inpatient stay.  
 Where more than one treatment location was recorded in the 
questionnaire (9% of responses), we assumed treatment occurred in the 
more intensive location. 
 For patients treated in A&E, we assumed a maximum time of 4 hours 
(as per government targets) after which they were equally likely to be 
transferred to HDU or ITU until DKA resolution. 
 Time on the acute wards was costed according to published per diems 
and time in the general ward was costed at the best practice tariff for 
extended days following DKA [15,16]. 
 A follow-up visit from the specialist diabetes team was costed as 
requiring 30 minutes of nurse time. 
 
Total costs were estimated as the sum of individual components. Specifically, 
total cost included the costs of an initial physician assessment, nursing time 
and diagnostic/laboratory tests, insulin and other drugs during the acute DKA 
phase, ward per diems during active treatment, and recovery (post-DKA), as 
well as a follow-up visit post admission if recorded. We did not include costs 
associated with any follow-up beyond an initial visit from a member of the 
diabetes specialist team, or the consequences of any precipitating factors, 
treating comorbidities, or on the cost of diabetes to society in general.  
 
  
Missing data and imputation  
A summary of the questionnaire data are shown in Table 3 in the online 
supplementary material. Because a number of variables had a high proportion 
of missing values, we used multiple imputation methods to infer values for 
missing values, assuming values were missing completely at random (MCAR). 
We performed predictive mean matching (PMM) using the Multivariate 
Imputation by Chained Equations Package in R statistical software (version 
3.3.2) [17]. Briefly, PMM estimates a regression model for each variable with 
missing values, and replaces each missing value with the value of the record 
with the closest match on the regressed predictors [18]. The regression model 
is used to estimate the similarity of the record with other non-missing 
observations rather than the missing value itself. Table 3 in the online 
supplementary material shows the variables with imputed values. We did not 
impute non-continuous variables such as flags indicating a particular blood test 
or imaging procedure. Instead, we imputed the continuously distributed sub-
totals for the individual components noted above (physician assessment, 
nursing time, diagnostic/laboratory tests, insulin and other drugs, ward per 
diems), and used the sum of these components to estimate total cost.  This 
allowed the estimated total cost to be based on observed values as much as 
possible while avoiding strong assumptions about the distribution of non-normal 
parameters. A comparison of the observed and imputed total costs is shown in 
Figure 1. 
 
Following data imputation, we tested the fit of different theoretical distributions 
to inform future modelling efforts.  We tested gamma and log-normal 
  
distributions using the fitdistrplus package and selected the preferred 
distribution on the basis of the Bayesian Information Criterion (BIC).   
 
Predictors of cost and length of stay  
We used linear regression to test a number of predictors of cost and length-of-
stay (LOS). These included age, gender, the number of previous DKA 
admissions, and flags indicating hypoglycaemia following resolution of DKA 
and whether DKA treatment followed JBDS guidelines. 
 
Clinical care staff  
To determine the amount of time spent by clinical care staff such as nurses and 
doctors in managing the patients, we sought expert opinion from a consultant 
in diabetes medicine. We determined the following minimum times that would 
be spent by clinical staff. A full list of allocated time, procedure and clinical staff 
is provided in Appendix 1 in the on line supplementary material. This was 
constructed by a one of the authors (KD) using the JBDS DKA guideline [19].  
 
Similarly, to be able to determine the costs associated with clinical care staff 
time we determined the hourly wage rages of a range of different staff. Sources 
of salaries and other costs are provided in Table 1. 
 
Costs of DKA were only considered from a hospital perspective and the 
admission of the patient to the resolution of DKA. Cost analysis however was 
done for the duration of DKA treatment and not the whole duration of the 
patients stay to provide an accurate picture of the impact of DKA and the 
associated costs with patient treatment. This allows us to determine the impact 
  
of DKA on the NHS but does not take into the account patient circumstance or 
comorbidities. These circumstances could be medical or social and many cases 
led to lengthier hospital stays and subsequently higher costs than would be the 
case of DKA alone.  
 
 
Results 
The mean cost per episode of DKA was £2064 per patient [95% confidence 
interval (CI): £1800, 2563], including physician and nursing time, laboratory and 
diagnostic assessments, intravenous insulin, and ward per diems. The mean 
time to DKA resolution was 22.3 hours (95% CI: 20.3, 24.3) and the mean total 
length of stay was 5.6 days (95% CI: 3.9, 7.2). 
 
We found that a theoretical log-normal distribution, with a log mean of 7.206 
and standard error of 0.05, had the best fit with the observed (imputed) 
distribution of total costs (BIC 4791.8) compared to a gamma distribution (BIC 
5031.8).  The empirical and theoretical distributions are shown in Figure 1. 
 
The distribution of patients by treatment area is shown in Table 2. The majority 
of patients were treated in acute medical units and general wards, with only 
one-third treated in higher intensity areas.  
 
Predictors of cost and length of stay  
An episode of hypoglycaemia following DKA had statistically significant impact, 
reducing the mean cost of an event by £935 (p=0.03). Males had a significantly 
  
shorter time to DKA resolution (-6.2 hours, p=0.003).  The other parameters 
were not statistically significant at 5 per cent. 
 
Transfer to HDU 
Initially according to the guidelines we determined the number of patients who 
should have been transferred to a high dependency unit (HDU). By observing 
three important factors 1) Bicarbonate concentration 2) pH and 3) potassium 
concentration, we determined that, according to the JBDS guidelines, 35% of 
the patients should have been treated in HDU or ITU. However only 4% of 
patients were actually treated in these areas. Not transferring them would most 
likely have resulted in higher cost for DKA treatment. A range of plausible 
reasons could influence whether the patient was moved to HDU or ITU, the 
most significant being the shortage or unavailability of beds [20]. Hence costs 
may have been influenced by institutional arrangements and capacity 
constraints.  
 
Hypoglycaemia 
Another factor which could impact on the length of stay was whether or not the 
patient had an episode of hypoglycaemia after their DKA treatment. Twenty 
eight percent of patients in our cohort had a hypoglycaemic episode. Somewhat 
surprisingly however, our data showed that an episode of hypoglycaemia was 
associated with a significant reduction in costs by £935. These data contradict 
previous work that show that hypoglycaemia is associated with a longer length 
of stay and increased mortality [21]. We are unable to explain this difference 
and clearly this is an area where more work needs to be done. 
 
  
Cost impact of precipitating causes 
As part of the analysis we also looked at precipitating factors that were 
associated with DKA. The nationally collected data used in this analysis 
showed that 77% of the patients provided information on their precipitating 
factors. Of those, 21% patients were not complying with their diabetes 
treatment; 5% had new-onset diabetes; and the remaining 51% were due a 
combination of other acute and non-acute illnesses. These data differentiated 
the present work from previous studies because of the granularity of the 
information that was obtained from individual patient level data.  
 
Discussion 
This study has shown that in 2014, the average cost of treating an episode of 
diabetic ketoacidosis in an adult patient in the UK was £2064 (95% CI: £1800, 
2563) 
 
The data collected as part of the national survey were not specifically collected 
for a health economic analysis to be conducted upon. However we were able 
to identify a pathway of treatment based on the JBDS DKA guideline which was 
used by the majority of hospitals who returned data. We were also able to 
determine the staff type and time required in each treatment step as well as 
being able to determine the impact of a range of physiological results upon the 
resolution of DKA. This allowed us to determine the cost associated with the 
treatment of DKA in a more granular fashion than has been done previously. 
The costs identified in this study however do not account for hospital overheads 
which are often included in Healthcare Resource Groups (HRG) codes and 
  
their associated cost calculation per event. HRG codes are groups of clinically 
similar treatments which use similar quantities of resource [22].   
 
Cost of DKA  
Direct healthcare costs 
The current study is one of the first to present the costs of DKA from a 
secondary care perspective. A previous study involved requesting data from 
primary care organisations on the costs associated with DKA admissions [23]. 
The authors stated that only 32% of the primary care organisations provided 
such information which showed that the average total cost of DKA was £1,438 
per patient. The report also stated median overall cost of treating DKA among 
the primary care organisations was £125,440 [23]. A more recent study 
(presented in abstract form only) reported data from a high risk sub-population 
of individuals who suffered from recurrent DKA events over a retrospective 
three-year period [24]. The resultant cost analysis of the data from that single 
centre study showed that the average cost per patient per year was £1,803.  
 
Productivity losses 
Previous work on the costs associated due to lost productivity in people with 
type 1 diabetes estimated that 37,000 work years are lost from premature death 
[25]. Furthermore, they showed that more than 830,000 sick days were taken 
by people with type 1 diabetes. From the prevalence figures we can estimate 
the work years lost and time taken off work due to sickness to be approximately 
12,000 and 27,000 years respectively. However, no work has been done which 
looks at the costs associated with productivity loss from DKA.  
 
  
By using forecasts of the population of people with diabetes increasing over the 
coming years and data on incidence rates of DKA, it is possible to assign values 
to future costs of DKA treatment. This is particularly possible using the crude 
prevalence rate of type 1 diabetes mentioned earlier; the crude prevalence rate 
of DKA events in the UK and the predicted yearly increase in the diabetes 
population. From this figure we can multiply the average patient cost for DKA 
and obtain a figure allowing us to determine the economic burden of the disease 
for the years to come.  
 
It may well be that the differences between costs in the UK and the USA are in 
part due to the higher number of people looked after in Level 2 (HDU) or Level 
3 (ITU) environments. These are more expensive areas within the hospital. Had 
the sicker patients been treated in these - more appropriate - clinical 
environments, then the overall costs would have been higher.  
 
There are several limitations to our data. The data used came from a 
retrospective convenience sample. The data collected were not in a form that 
was easily usable for health economic analysis and many assumptions had to 
be made. In addition, we did not add on further salary costs (e.g. employers ‘on 
costs’) or costs associated with the treatments of co-morbidities because these 
were very disparate. Our sample size was too small to make general 
assumptions about these co-morbidities. In addition, we could not cost for 
recurrent readmissions because the 283 cases of DKA represented 281 
individual patients.  However, the major strengths of our data are that it was 
collected from across the UK, and that data were available for a large number 
  
for all stages of the patient journey from which appropriate calculations could 
be made.  
 
In summary, to treat an episode of DKA in an adult patient in the UK in 2014 
cost, on average, £2064 (95% CI: £1800, 2563). Many assumptions were made 
to allow these calculations, but as the number of people with diabetes 
increases, it is likely that the number of people admitted with DKA will also 
increase. In addition, given the many assumptions made it is likely that the true 
costs of an episode of DKA are much higher. These data should be used to 
enable funders to plan for future costs associated with this potentially life-
threatening medical emergency.  
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Legends to Tables, Figure and Appendices 
 
Table 1 - Cost components - unit prices  
Table 2 - Patient distribution by treatment area 
Figure 1 - A comparison of the observed and imputed total costs  
 
Online supplementary data 
 
Table 3 – Data collection with percentage of missing data and imputed data 
Table 4 – Costs by component 
 
Appendix 1 - A full list of allocated time, procedure and clinical staff needed to 
treat an episode of DKA  
  
Table 1 
Cost Component 
Unit Cost 
(£) 
Hospital facilities  
Level 1: General Ward – per day 428.49* 
Level 2: HDU – per day 889.14* 
Level 3: ITU – per day 2004.45* 
Acute Medical Unit (AMU) - per day 428.49* 
A&E – per day 2552.00* 
Other wards – per day 428.49* 
Variable  
Healthcare staff (per hour)  
Staff Nurse (Band 6) 13.32** 
Specialist Registrar (Middle band) 23.76Ƭ 
Junior Doctor 14.39Ƭ 
Diabetes Specialist Nurse (Band 6) 16.70** 
Variable  
Investigations  
X-Ray 25.00§ 
Laboratory blood tests 1.00§ 
Electrocardiogram (ECG) 32.00§ 
 Urine test strip 0.43¥ 
 Intravenous insulin 5.24∞ 
1 litre 0.9% sodium chloride solution with potassium 2.20¶ 
* Data taken from Reference [15] 
** Data taken from Reference [26] 
Ƭ Data taken from [27] 
§ Data taken from [28] 
¥ Data taken from [29] 
∞ Data taken from [30] 
  
¶ Data taken from  [31] 
  
Table 2 
 
TREATMENT AREA DISTRIBUTION (%) 
General ward 16 
High Dependency Unit 14 
Intensive Care Unit 10 
Acute Medical Unit 39 
Accident & Emergency 10 
Other 2 
Assumption made 9 
 
  
  
Figure 1: Observed vs Imputed Total Costs 
 
 
  
  
Figure 2: Empirical vs Theoretical Total Costs 
 
 
 
